JP Morgan Chase’s BioLineRX BLRX Stock Holding History

JP Morgan Chase’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-375	Closed	-$1.11K	–	7092
2025 Q1	$1.11K	Buy	+375	New	+$1.51K	﹤0.01%	6617
2024 Q4	–	Hold	0	–	-$1	–	7401
2024 Q3	–	Sell	-38	Closed	-$1.04K	–	7366
2024 Q2	$850	Buy	+38	New	+$1.02K	﹤0.01%	6635
2024 Q1	–	Sell	-574	Closed	-$36.1K	–	7432
2023 Q4	$36.1K	Buy	+574	New	+$35.5K	﹤0.01%	6105
2018 Q1	–	Sell	-48	Closed	-$31K	–	5380
2017 Q4	$31K	Buy	+48	New	+$31.6K	﹤0.01%	5049

Other funds holding BLRX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NRG

Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

JP Morgan Chase's BLRX Position: Q2 2025 in Review

JP Morgan Chase sold out of BioLineRX (BLRX) in Q2 2025, closing a stake of 375 shares — an estimated $1.11K sold.

JP Morgan Chase first reported a position in BLRX in Q4 2017 and held it in 4 quarters. The position peaked at $36.1K in Q4 2023. 17 funds tracked by Wall St. Rank hold BLRX as of Q2 2025.

JP Morgan Chase reported no remaining BioLineRX position as of Q2 2025 after selling out during the quarter.
JP Morgan Chase sold 375 BioLineRX shares in Q2 2025, an estimated $1.11K.
JP Morgan Chase first reported a position in BioLineRX in Q4 2017 and held it in 4 quarters.
JP Morgan Chase's BioLineRX position peaked at $36.1K in Q4 2023.
17 funds tracked by Wall St. Rank held BioLineRX as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.